ImmuPharma plc (LON:IMM – Get Free Report) shares traded down 3.4% during mid-day trading on Tuesday . The company traded as low as GBX 8.20 and last traded at GBX 8.98. 10,016,895 shares changed hands during mid-day trading, an increase of 149% from the average session volume of 4,020,944 shares. The stock had previously closed at GBX 9.30.
ImmuPharma Stock Performance
The stock’s 50 day simple moving average is GBX 6.60 and its 200 day simple moving average is GBX 7.59. The firm has a market cap of £38.71 million, a P/E ratio of -8.65 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
